PRKG1 and malaria: However, to fully realizethe benefit of dual PI4Kβ and PKG inhibitions for this series,further optimization will aim to improve potency against PfPKG, de-risk human host kinase targets including mTOR, investigateselectivity over other human protein and lipid kinases, and optimizesolubility for the delivery of potent drugs against malaria.